Department of Neurological Surgery, California Center for Pituitary Disorders, University of California, San Francisco, CA 94143, USA.
Neurosurg Clin N Am. 2012 Oct;23(4):669-78. doi: 10.1016/j.nec.2012.06.010. Epub 2012 Aug 17.
Prolactinomas are the most common hormone-secreting pituitary adenomas, comprising 40% of all pituitary tumors. Prolactinomas present a unique challenge for clinicians, as these tumors are amenable to either medical or surgical treatments based on patients' comorbidities, tolerance to medical treatment, and the response of tumors to medical treatment. Rare prolactinomas that are unresponsive to either medical or surgical treatment modalities may be responsive to radiation therapy. This article reviews the recent advancements in the management of prolactinomas.
催乳素瘤是最常见的激素分泌性垂体腺瘤，占所有垂体肿瘤的 40%。催乳素瘤对临床医生来说是一个独特的挑战，因为这些肿瘤可以根据患者的合并症、对药物治疗的耐受性以及肿瘤对药物治疗的反应，采用药物或手术治疗。对于那些对药物或手术治疗均无反应的罕见催乳素瘤，可能对放射治疗有反应。本文综述了催乳素瘤治疗的最新进展。
